CLINICAL RESEARCH and INNOVATION
Current data from a clinical study on patients with colon cancer demonstrated that the Lonicera Tablet Matrix was successful on delivering more than 85% of each tablet bacteria load, in a viable state to a targeted area in the gut. The probiotic remedy used for this trial, was the "ProBion Clinica" product by Wasa Medical. The ProBion probiotic remedy changed the bacterial profile in the colon of the subjects to a profile similar to healthy individuals as well as it changed the methylation pattern in the tumour cells, which could result in activation of tumour suppressor genes.
Lonicera Innovation AB, is a biotechnology research company with the distinct objective to link and highlight the effects of probiotics (beneficial non-pathogenic gut bacteria) to our most common disorders.
We perform both clinical and basic science studies regarding the effect of probiotics on various different diseases, such as colon cancer, metabolic diseases, celiac disease, infertility and irritable bowel syndrome. Our main center of research is located in Goteborg, Sweden.
We also collaborate with universities, hospitals and institutions around the world, such as the University of Katmandu, Nepal, a country where extreme poverty and a practically non-existent health care system are the norm. We believe that our research at Lonicera Innovation AB can greatly enhance the health and quality of life of these people.
In order to sustain a high yield of viable probiotic bacteria in the intestine, we require that the vehicle used to introduce them in the gut is as resistant as possible to gastric juices and bile acids. In addition, employing an accurate gut navigation delivery system, carrying High Quality - High Viability probiotics loads and precise Time Triggered Targeting efficacy are paramount requirements for effective reliable results in achieving our objectives.
The number and amount of viable bacteria is supervised using Flow Cytometric analysis. This method is direct and enables us to better monitor the dose-response outcome. We use the unique patented formulation of the Lonicera Tablet Matrix to ensure these features in every step of our studies. Its sustained storage viability together with its slow-release profile is absolutely unique to the Lonicera Matrix.